Ország: Dél-afrikai Köztársaság
Nyelv: angol
Forrás: South African Health Products Regulatory Authority (SAHPRA)
Lennon
DILATAM 60 mg TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): DILATAM 60 mg TABLETS COMPOSITION: Each tablet contains 60 mg diltiazem hydrochloride. PHARMACOLOGICAL CLASSIFICATION: A 7.1 Vasodilators, hypotensives. PHARMACOLOGICAL ACTION: Dilatam is a calcium channel blocker which inhibits the influx of calcium ions during membrane depolarization of cardiac and vascular smooth muscle. The resultant pharmacological effects on the cardiovascular system include depression of mechanical contraction of myocardial and smooth muscle and depression of both impulse formation (automatically) and conduction velocity. Dilatam dilates the coronary arteries and arterioles and therefore increases myocardial oxygen supply. Dilatam dilates peripheral arterioles and reduces the total peripheral resistance (afterload) against which the heart works. This unloading of the heart reduces myocardial energy consumption and oxygen requirements. Dilatam decreases sino-atrial and atrioventricular conduction and prolongs the AV node effective and functional refractory periods (ERP, FRP). INDICATIONS: 1) For the management of angina pectoris including Prinzmetal's variant angina. 2) For the treatment of mild to moderate hypertension. CONTRA-INDICATIONS: Pregnancy and women of child bearing age. Patients known to be hypersensitive to Dilatam. Dilatam should not be administered to patients with decompensated cardiac insufficiency, sick sinus syndrome, conduction disturbances (sino-atrial or atrioventricular block) and bradycardia (pulse rate less than 55/min.), and hypotension (less than 90 mm Hg systolic). Dilatam should not be administered to patients with liver and kidney impairment. The administration of diltiazem is contra-indicated in patients with porphyria. WARNINGS: Safe use in children has not been establis Olvassa el a teljes dokumentumot